- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04776239
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD) (ACESO-IHD)
September 20, 2023 updated by: Carlos Enrique Alfonso, MD, University of Miami
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease.
The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carlos E Alfonso, MD
- Phone Number: (305) 2437589
- Email: calfonso@med.miami.edu
Study Contact Backup
- Name: Russell G Saltzman, MSPH
- Phone Number: 305-243-1152
- Email: R.Saltzman@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Russell G Saltzman, MSPH
- Phone Number: 305-243-1152
- Email: R.Saltzman@med.miami.edu
-
Contact:
- Carlos E Alfonso, MD
- Phone Number: 305-243-5554
- Email: calfonso@med.miami.edu
-
Principal Investigator:
- Carlos E Alfonso, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Be ≥ 18 years of age (males and females).
- Provide written informed consent.
- Have a diagnosis of symptomatic ischemic heart disease (IHD) and an indication for standard-of-care coronary angiography.
- Have Diabetes Mellitus (DM) type 2 documented by glycated hemoglobin (HbA1C) > 7%, or on medical therapy for diabetes.
Exclusion Criteria:
- Be younger than 18 years of age.
- Have history of prior myocardial Infarction and revascularization.
- Have a baseline glomerular filtration rate (GFR) <30 ml/min 1.73m2 estimated using the Modification of Diet for Renal Disease (MDRD) formula.
- Have poorly controlled blood glucose levels with hemoglobin A1C > 8.5% in the previous 3 months.
- Have a history of proliferative retinopathy or severe neuropathy requiring medical treatment.
- Have an indication for standard-of-care surgical (including valve surgery, placement of left-ventricular assist device) or percutaneous intervention for the treatment of valvular heart disease (including valvuloplasty).
- Have known hypersensitivity or contraindication to aspirin; both heparin and bivalirudin; all available P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor); or any zotarolimus, cobalt, chromium, nickel, tungsten, acrylic, or fluoropolymers; or hypersensitivity to contrast media that cannot be adequately premedicated.
- Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/microliter (uL) or platelet values < 100,000/uL without another explanation (per investigator discretion).
- Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal.
- Have a bleeding diathesis or coagulopathy (INR > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions.
- Be an organ transplant recipient or have a history of organ or cell transplant rejection.
- Have a clinical history of malignancy within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively-treated basal cell or squamous cell carcinoma, or cervical carcinoma.
- Have a condition that limits lifespan to < 1 year.
- Have a history of drug or alcohol abuse within the past 24 months.
- Be serum positive for HIV, hepatitis B surface antigen (sAg), or viremic hepatitis C.
- Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
- Be pregnant, nursing, or of childbearing potential and not on contraceptive medications. (May participate if on 2 forms of contraceptives).
- Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up.
- Coronary lesions with restenosis or heavy calcification.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group
Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
|
1 single intravenous infusion
Other Names:
|
Experimental: Group 2: Placebo Group
Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
|
Placebo delivered via peripheral intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR
Time Frame: 6 months (post-infusion)
|
Coronary Flow Reserve (CFR) as measured via cardiac catheterization angiography
|
6 months (post-infusion)
|
Post-PCI coronary artery endothelial function as assessed via FFR
Time Frame: 6 months (post infusion)
|
Fractional Flow Reserve (FFR) as measured via cardiac catheterization angiography
|
6 months (post infusion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target lesion lumen loss
Time Frame: 6 months (post-infusion)
|
Target lesion lumen loss as assessed by quantitative coronary angiography (QCA).
|
6 months (post-infusion)
|
Flow Mediated Diameter Percentage (FMD%)
Time Frame: 6 months post-infusion
|
FMD% is measured via brachial artery ultrasound
|
6 months post-infusion
|
EPC-CFUs levels
Time Frame: 6 months post-infusion
|
Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples.
|
6 months post-infusion
|
Circulating angiogenic factors marker levels
Time Frame: 6 months post-infusion
|
Circulating angiogenic marker levels including Protein Kinase B, Stromal Cell Derived Factor 1 (SDF-1), Notch, Vascular Endothelial Growth Factor (VEGF) and Colony Forming Units (CFU) will be assessed from blood samples.
|
6 months post-infusion
|
Circulating inflammatory markers
Time Frame: 6 months post-infusion
|
Circulating inflammatory markers including Cluster of Differentiation (CD) 3 CD 25 or CD 3 CD 69 will be assessed from blood samples.
|
6 months post-infusion
|
Seattle Angina Questionnaire (SAQ) Angina Frequency
Time Frame: 6 months post-infusion
|
SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life.
|
6 months post-infusion
|
EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire
Time Frame: 6 months post-infusion
|
EQ-5D Quality of Life Questionnaire has a total score ranging from 0-10 with higher scores indicating better quality of life.
|
6 months post-infusion
|
EQ-5D Quality of life Questionnaire Overall Health Status Question
Time Frame: 6 months post-infusion
|
EQ-5D Quality of Life Questionnaire Overall Health Status question has a total score ranging from 0-100 with higher scores indicating better quality of life.
|
6 months post-infusion
|
Short Form (SF) 36 Questionnaire Quality of Life Questionnaire
Time Frame: 6 months post-infusion
|
SF 36 Quality of Life Questionnaire consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale.
Lower scores indicate the more disability, and higher scores indicate less disability.
|
6 months post-infusion
|
International Index of Erectile Function (IIEF) Questionnaire
Time Frame: 6 months post-infusion
|
IIEF is a 15 item questionnaire to be completed by males only, with scores ranging from 0-75.
Higher scores indicate better male sexual function/quality of life.
|
6 months post-infusion
|
Sexual Quality of Life - Females (SQOL-F) Questionnaire
Time Frame: 6 months post-infusion
|
SQOL-F Questionnaire is an 18 item questionnaire in which female participants are asked to record responses on a 6-point Likert scale (completely agree to completely disagree).
Total score can range from 18 to 108.
Higher scores indicate better female sexual quality of life.
|
6 months post-infusion
|
Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)
Time Frame: 1 month post infusion
|
TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias or atrial fibrillation.
TE-SAEs will be assessed by treating physician.
|
1 month post infusion
|
Incidence of Major Adverse Cardiac Events (MACE)
Time Frame: 12 months
|
Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal MI.
MACE will be assessed by treating physician.
|
12 months
|
Rates of Adverse Events
Time Frame: 12 months
|
Rates of treatment emergent adverse event (AE) and serious adverse event (SAE) as assessed by treating physician will be reported.
|
12 months
|
Number of participants with abnormal lab values
Time Frame: 12 months
|
Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported.
Clinical significance will be assessed by treating physician.
|
12 months
|
Number of participants with Target Vessel Failure
Time Frame: 12 months
|
Number of participants with target vessel failure will be reported.
Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Carlos E Alfonso, MD, University of Miami
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 16, 2021
Primary Completion (Estimated)
July 16, 2024
Study Completion (Estimated)
July 16, 2024
Study Registration Dates
First Submitted
February 26, 2021
First Submitted That Met QC Criteria
February 26, 2021
First Posted (Actual)
March 1, 2021
Study Record Updates
Last Update Posted (Actual)
September 22, 2023
Last Update Submitted That Met QC Criteria
September 20, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20200874
- 1R01HL134558-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on 100 million Allogeneic Mesenchymal Human Stem Cells
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedDiabetes Mellitus, Type 2United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedProstate CancerUnited States
-
Joshua M HareThe Emmes Company, LLCCompletedMyocardial Infarction | Chronic Ischemic Left Ventricular DysfunctionUnited States
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
Michael A. MatthayMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedAcute Respiratory Distress SyndromeUnited States
-
Longeveron Inc.TerminatedHypoplastic Left Heart SyndromeUnited States
-
Bernard (Barry) BaumelCompleted
-
Clinica Santa Clarita, MexicoWithdrawnKnee OsteoarthritisMexico
-
University of North Carolina, Chapel HillRecruitingIdiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung DiseaseUnited States
-
Supergenics Life Science Sdn. Bhd.Not yet recruitingDiabetic Foot Ulcer